Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapse-Remitting Multiple Sclerosis”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Large-scale testing (Phase 3)Study completedNCT01838668
What this trial is testing

An Efficacy and Safety Study of BG00012 (Dimethyl Fumarate) in Asian Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)

Who this might be right for
Relapsing-Remitting Multiple SclerosisMultiple Sclerosis
Biogen 225
Post-approval studies (Phase 4)Study completedNCT01395316
What this trial is testing

Alemtuzumab on Surrogate Markers of Disease Activity and Repair Using Advanced MRI Measures in Subjects With Relapsing Remitting Multiple Sclerosis

Who this might be right for
Multiple Sclerosis
University of Chicago 8
Post-approval studies (Phase 4)Ended earlyNCT01490840
What this trial is testing

Effect of Physical ACtivity in Fingolimod Treated patiEnts (PACE) With Relapsing-remitting Multiple Sclerosis

Who this might be right for
Fatigue in Multiple Sclerosis
Novartis Pharmaceuticals 178
Testing effectiveness (Phase 2)Study completedNCT01428726
What this trial is testing

A Phase IIa Study of NT-KO-003 for Multiple Sclerosis

Who this might be right for
Relapsing Remitting Multiple Sclerosis
Neurotec Pharma 99
Not applicableLooking for participantsNCT06569550
What this trial is testing

Fatigue Alleviation Through Neuromodulating Therapy in Multiple Sclerosis

Who this might be right for
Multiple Sclerosis, Relapsing-RemittingFatigue
Danish Research Centre for Magnetic Resonance 60
Testing effectiveness (Phase 2)Study completedNCT02686788
What this trial is testing

TMP001 in Relapsing-remitting Multiple Sclerosis

Who this might be right for
Remitting-Relapsing Multiple Sclerosis
Dr. Frank Behrens 9
Post-approval studies (Phase 4)Study completedNCT01420055
What this trial is testing

Fingolimod -Response According to Coping - Evaluation

Who this might be right for
Multiple Sclerosis, Relapsing-Remitting
Novartis Pharmaceuticals 189
Testing effectiveness (Phase 2)Study completedNCT00870740
What this trial is testing

Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) in Participants With Multiple Sclerosis Who Have Completed Study 205MS201 (NCT00390221) to Treat Relapsing-Remitting Multiple Sclerosis

Who this might be right for
Relapsing-Remitting Multiple Sclerosis
Biogen 517
Not applicableStudy completedNCT05029206
What this trial is testing

Hematopoietic Stem Cell Transplantation for Treatment of Multiple Sclerosis in Sweden

Who this might be right for
Multiple SclerosisMultiple Sclerosis, Relapsing-Remitting
Uppsala University 174
Not applicableStudy completedNCT07514104
What this trial is testing

Extracorporeal Shock Wave Therapy in Enhancing Sensitivity and Postural Stability in Multiple Sclerosis

Who this might be right for
Multiple SclerosisMultiple Sclerosis (MS) - Relapsing-remittingSensorimotor Gait Disorder
Furkan Bilek 54
Not applicableStudy completedNCT00818038
What this trial is testing

A Proof of Concept Study to Evaluate the Effectiveness of Tysabri in Relapsing Remitting Multiple Sclerosis (RRMS) Patient Bladder Function

Who this might be right for
Relapsing-Remitting Multiple Sclerosis
Biogen 30
Not applicableStudy completedNCT01108887
What this trial is testing

An Observational Study for the Assessment of Adherence, Effectiveness and Convenience of Rebif® Treatment in Relapsing Multiple Sclerosis Patients Using RebiSmart™.

Who this might be right for
Multiple Sclerosis, Relapsing-Remitting
Merck KGaA, Darmstadt, Germany 912
Post-approval studies (Phase 4)Ended earlyNCT02901106
What this trial is testing

Monitoring of Patients Followed for a Multiple Sclerosis and Treated by Dimethyl-fumarate

Who this might be right for
Multiple Sclerosis, Relapsing-Remitting
Fondation Ophtalmologique Adolphe de Rothschild 11
Early research (Phase 1)Study completedNCT00645749
What this trial is testing

Helminth-induced Immunomodulation Therapy (HINT) in Relapsing-remitting Multiple Sclerosis

Who this might be right for
Relapsing Remitting Multiple Sclerosis
University of Wisconsin, Madison 17
Early research (Phase 1)Study completedNCT02601885
What this trial is testing

A Multiple Dose Study of ABT-555 in Subjects With Relapsing Forms of Multiple Sclerosis

Who this might be right for
Multiple Sclerosis
AbbVie 20
Not applicableStudy completedNCT01456416
What this trial is testing

Glatiramer Acetate for Multiple Sclerosis With Autoimmune Comorbidities

Who this might be right for
Relapsing Remitting Multiple Sclerosis
University of Southern California 10
Not applicableStudy completedNCT01943526
What this trial is testing

Ireland Natalizumab (TYSABRI) Observational Program

Who this might be right for
Relapsing-Remitting Multiple Sclerosis
Biogen 191
Post-approval studies (Phase 4)Ended earlyNCT00203047
What this trial is testing

Assessment Study of Steroid Effect in Relapsing Multiple Sclerosis Subjects Treated With Glatiramer Acetate

Who this might be right for
Relapsing Remitting Multiple Sclerosis
Teva Branded Pharmaceutical Products R&D, Inc. 414
Testing effectiveness (Phase 2)Study completedNCT00324506
What this trial is testing

Safety and Efficacy of Cellcept and Avonex as Combination Treatment in Multiple Sclerosis

Who this might be right for
Multiple Sclerosis
University of Texas Southwestern Medical Center 43
Testing effectiveness (Phase 2)Study completedNCT00097331
What this trial is testing

Three Months Treatment With SB683699 In Patients With Relapsing Multiple Sclerosis

Who this might be right for
Multiple Sclerosis, Relapsing-Remitting
GlaxoSmithKline 261
Next Page